The FBLN1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B-cell line, designed for loss-of-function studies of the FBLN1 gene. FBLN1 encodes fibulin-1, an extracellular matrix (ECM) glycoprotein that mediates cell-matrix interactions and contributes to tissue integrity. In this product, CRISPR/Cas9-mediated gene disruption has been employed to introduce targeted mutations within the FBLN1 locus, creating a heterogeneous pool of cells with ablated gene function. This polyclonal format provides a versatile tool for investigating the roles of fibulin-1 in processes such as adhesion, migration, and signaling in a B-lymphoid context, without the clonal artifacts that may arise from single-cell-derived lines. The cell population is suitable for a broad range of experimental applications requiring bulk knockout phenotypes.
The Raji host cell line originates from a human Burkitt lymphoma and is characterized by its Epstein-Barr virus (EBV)-positive status. These B cells are widely employed in immunological research due to their ability to recapitulate aspects of B-cell biology, including adaptive immune responses and antibody production. Raji cells express surface markers characteristic of mature B lymphocytes and have been instrumental in studying B-cell receptor signaling, apoptosis, and lymphomagenesis. Their robust growth in suspension culture facilitates large-scale experiments and high-throughput screening. The EBV-positive background may influence cellular signaling networks, making this cell line particularly relevant for investigating viral contributions to B-cell malignancies and for exploring ECM-related interactions in a transformed lymphoid microenvironment.
Fibulin-1 functions within the ECM scaffold by interacting with multiple binding partners, including fibronectin, laminin, integrin ??5??1, and perlecan, thereby bridging structural proteins with cell surface receptors. FBLN1 is transcriptionally regulated by upstream factors such as TGF-??, integrin-mediated signals, and mechanical stretch, positioning it at the intersection of biochemical and biomechanical cues. Upon FBLN1 disruption, downstream targets including integrins, matrix metalloproteinases, and focal adhesion kinase (FAK) are altered, leading to reorganization of the focal adhesion complex that comprises FAK, paxillin, and Src. This perturbation disrupts integrin ??1-mediated signaling and downstream cascades such as the TGF-?? pathway, collectively affecting cell adhesion, migration, survival, and proliferation. The interplay between fibulin-1 and these molecular components underscores its role in maintaining tissue architecture and regulating cellular behavior.
In the Raji B-lymphoma context, FBLN1 knockout provides a unique model to dissect how ECM-derived signals influence malignant B-cell phenotypes. Lymphoma cells rely on integrin-mediated interactions with fibronectin and laminin within lymphoid niche microenvironments for homing, retention, and expansion. Ablation of fibulin-1 in Raji cells is expected to compromise these adhesive interactions, potentially impairing cell spreading, motility, and survival signaling. This system thus enables investigation of the molecular basis by which ECM proteins modulate B-cell malignancies, including the crosstalk between fibulin-1 and the TGF-?? pathway that is frequently dysregulated in lymphoproliferative disorders. Furthermore, the polyclonal nature of the knockout population mimics the heterogeneity of tumor cell populations, offering a more physiologically relevant model than monoclonal counterparts for studying mechanisms of lymphoma progression and metastasis.
Researchers can employ the FBLN1 Knockout Raji Polyclonal Cells in a variety of applications, including Western blotting to confirm target protein depletion, adhesion assays on fibronectin or laminin substrates to quantify cell-matrix attachment, and transwell migration/invasion assays to assess chemotactic responses. Proliferation curves and flow cytometric analysis of integrin surface expression provide additional phenotypic readouts. Transcriptomic profiling by RNA-seq can reveal global gene expression changes associated with fibulin-1 loss. These applications support studies focused on the role of ECM in B-cell lymphoma, validation of fibulin-1 as a therapeutic target in lymphoproliferative disorders, and exploration of how integrin and TGF-?? signaling networks are rewired upon ECM perturbation. For additional technical details and ordering information, please contact Ascent Research.
